A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors
Status:
Completed
Trial end date:
2020-07-15
Target enrollment:
Participant gender:
Summary
A Phase I Study to Evaluate the Safety,Tolerability and Pharmacokinetics of RC48-ADC for
Injection in Subjects With Advanced Malignant Solid Tumors With HER2-positive